MPM BioVentures 2014, L.P. sold $446k of HOWL
owner at Werewolf Therapeutics, Inc.. 276,017 shares at an average of $1.62, traded Oct 27, 2025, filed Oct 29, 2025.
Score components
- +12Role10% owner
- +17Trade size$446k at market
- 0Share of holdings soldSold 4.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -35.9%, 3m -54.2%, 6m -56.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000374, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 27, 2025 | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -72,709 | $1.72 | $125k | 6,645,961 | Oct 29, 2025 |
| Oct 28, 2025 | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -69,068 | $1.64 | $113k | 6,576,893 | Oct 29, 2025 |
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -134,240 | $1.55 | $208k | 6,442,653 | Oct 29, 2025 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $45k 143,199 shares | -100% | |
| 29Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $47k 157,084 shares | -52% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $146k 416,911 shares | -9% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $174k 448,836 shares | -9% | |
| 38Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $254k 678,226 shares | -12% | |
| 13Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $28k 76,928 shares | -20% | |
| 14Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $43k 105,565 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $64k 139,803 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $66k 141,106 shares | -18% | |
| 17Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $87k 191,762 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.